Published in Alcohol Alcohol on March 01, 1995
Study of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic | NCT00381043
Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction (2012) 2.64
Management of alcohol dependence in patients with liver disease. CNS Drugs (2013) 2.35
Acamprosate and naltrexone treatment effects on ethanol and sucrose seeking and intake in ethanol-dependent and nondependent rats. Psychopharmacology (Berl) (2009) 1.13
A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addict Behav (2007) 1.11
Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res (2011) 1.10
Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate. Neuropsychopharmacology (2011) 1.08
Medical treatment of alcohol dependence: a systematic review. Int J Psychiatry Med (2011) 1.03
Design of naltrexone-loaded hydrolyzable crosslinked nanoparticles. Int J Pharm (2002) 0.91
The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. Psychopharmacology (Berl) (2009) 0.87
The clinical pharmacology of acamprosate. Br J Clin Pharmacol (2014) 0.86
Pharmacological approaches to reducing craving in patients with alcohol use disorders. CNS Drugs (2014) 0.86
Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence. CNS Neurol Disord Drug Targets (2010) 0.86
Safety and efficacy of acamprosate for the treatment of alcohol dependence. Subst Abuse (2013) 0.86
Influence of cue exposure on inhibitory control and brain activation in patients with alcohol dependence. Front Hum Neurosci (2012) 0.85
The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies. Alcohol Clin Exp Res (2013) 0.85
Does alexithymia explain variation in cue-elicited craving reported by methamphetamine-dependent individuals? Am J Addict (2012) 0.84
An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate. Eur Neuropsychopharmacol (2015) 0.82
Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models. Addict Biol (2016) 0.80
Studies on in vitro availability, degradation, and thermal properties of naltrexone-loaded biodegradable microspheres. Drug Dev Ind Pharm (2011) 0.80
Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility. Ther Clin Risk Manag (2012) 0.80
The associations between self-consciousness, depressive state and craving to drink among alcohol dependent patients undergoing protracted withdrawal. PLoS One (2013) 0.78
A dysbiotic subpopulation of alcohol-dependent subjects. Gut Microbes (2015) 0.76
Acamprosate in the treatment of alcoholism: a budget impact analysis for the National Health Service in Italy. Subst Abuse Rehabil (2012) 0.76
The development of acamprosate as a treatment against alcohol relapse. Expert Opin Drug Discov (2014) 0.76
Pharmacotherapy for alcohol use disorder: current and emerging therapies. Harv Rev Psychiatry (2015) 0.76
Acamprosate: a new tool in the battle against alcohol dependence. Neuropsychiatr Dis Treat (2006) 0.76
Metabotropic and ionotropic glutamate receptors as potential targets for the treatment of alcohol use disorder. Neurosci Biobehav Rev (2017) 0.75
Is there evidence for effectiveness of acamprosate in maintaining abstinence in alcohol dependent patients? Psychiatry (Edgmont) (2005) 0.75
Pharmacoprophylaxis of alcohol dependence: Review and update Part II: Efficacy. Indian J Psychiatry (2007) 0.75
Advances in alcoholic liver disease: An update on alcoholic hepatitis. World J Gastroenterol (2015) 0.75
The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) (1985) 7.53
Radioimmunodetection of human colorectal cancers by an anti-tumour monoclonal antibody. Lancet (1982) 1.71
Comparison of lateral thermal spread using monopolar and bipolar diathermy, the Harmonic Scalpel and the Ligasure. Br J Surg (2010) 1.62
Hypertension and impaired renal function accompany juvenile obesity: the effect of prenatal diet. Kidney Int (2007) 1.56
Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol (1998) 1.51
Adverse drug reaction monitoring: doing it the French way. Lancet (1985) 1.41
Monoclonal antigranulocyte antibody imaging in inflammatory bowel disease: a preliminary report. Nucl Med Commun (1992) 1.39
111In-labelled leucocyte imaging in vascular graft infection. Br J Surg (1989) 1.39
Thrombopoietin rescues in vitro erythroid colony formation from mouse embryos lacking the erythropoietin receptor. Proc Natl Acad Sci U S A (1996) 1.39
Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm (1999) 1.30
Plasma and cerebrospinal fluid concentrations of paracetamol after a single intravenous dose of propacetamol. Br J Clin Pharmacol (1992) 1.24
Validity of the geometric mean correction in the quantification of whole bowel transit. Nucl Med Commun (1985) 1.19
Efficacy of reversible inhibitors of monoamine oxidase-A in various forms of depression. Acta Psychiatr Scand Suppl (1990) 1.18
MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate. Br J Cancer (2004) 1.17
Pain complaints in depressed inpatients. Psychopathology (2001) 1.11
A method for measurement and statistical analysis of large numbers of experimental tracings. J Pharm Pharmacol (1967) 1.11
Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia (1997) 1.08
The characteristics of blood-borne radiolabels and the effect of anti-mouse IgG antibodies on localization of radiolabeled monoclonal antibody in cancer patients. J Nucl Med (1985) 1.07
Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol (1996) 1.06
Imaging of pancreatic and colorectal cancer using antibody fragments: a preliminary evaluation. Eur J Surg Oncol (1988) 1.04
131I and 111In-labelled monoclonal antibody imaging of primary lung carcinoma. Nucl Med Commun (1986) 1.03
Antigenicity of newly established colorectal carcinoma cell lines. Br J Cancer (1986) 1.00
Impulsivity: a relevant dimension in depression regarding suicide attempts? J Affect Disord (1999) 1.00
The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia (1998) 0.99
neptune, a Krüppel-like transcription factor that participates in primitive erythropoiesis in Xenopus. Curr Biol (2001) 0.98
The localization of an anti-tumour monoclonal antibody (791T/36) in gastrointestinal tumours. Br J Surg (1984) 0.97
Hepatic perfusion index in the diagnosis of overt metastatic colorectal cancer. Nucl Med Commun (1990) 0.97
Does increasing dose improve efficacy in patients with poor antidepressant response: a review. Acta Psychiatr Scand (2000) 0.97
Adaptation of the tail suspension test to the rat. J Pharmacol (1987) 0.97
[Toxicity and pharmacokinetics of zirconium oxychloride in mice and rats]. J Pharmacol (1984) 0.96
In vivo participation of a high potential iron-sulfur protein as electron donor to the photochemical reaction center of Rubrivivax gelatinosus. Biochemistry (1995) 0.95
IDS-C and IDS-sr: psychometric properties in depressed in-patients. J Affect Disord (1999) 0.95
Tendon disorders with fluoroquinolones. Therapie (1997) 0.95
[Favorable effect of yohimbine hydrochloride on orthostatic hypotension induced by clomipramine]. Nouv Presse Med (1979) 0.94
Concordance between self-report and clinician's assessment of depression. J Psychiatr Res (1999) 0.94
Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol (1990) 0.94
The Edinburgh Postnatal Depression Scale (EPDS) and the detection of major depressive disorders in early postpartum: some concerns about false negatives. J Affect Disord (2000) 0.93
Comorbidity of personality disorders and unipolar major depression: a review. J Affect Disord (1996) 0.93
Total and free ketoprofen in serum and synovial fluid after intramuscular injection. Clin Pharmacol Ther (1987) 0.93
Ermap, a gene coding for a novel erythroid specific adhesion/receptor membrane protein. Gene (2000) 0.92
Effect of bran particle size on gastric emptying and small bowel transit in humans: a scintigraphic study. Gut (1995) 0.92
Imaging of primary and metastatic colorectal cancer using an 111In-labelled antitumour monoclonal antibody (791T/36). Nucl Med Commun (1985) 0.92
Effect of a novel 5-HT3 receptor agonist MKC-733 on upper gastrointestinal motility in humans. Aliment Pharmacol Ther (2003) 0.91
Clinical pharmacokinetics of nonsteroidal anti-inflammatory drugs in the cerebrospinal fluid. Biomed Pharmacother (1989) 0.91
Caffeine, a metabolite of theophylline during the treatment of apnea in the premature infant. J Pediatr (1979) 0.90
The effect of the nasal cycle on mucociliary clearance. Clin Otolaryngol Allied Sci (2001) 0.90
Novel MRI tests of orocecal transit time and whole gut transit time: studies in normal subjects. Neurogastroenterol Motil (2013) 0.90
Production and characterization of 188Re-C595 antibody for radioimmunotherapy of transitional cell bladder cancer. J Nucl Med (2001) 0.90
[Serotonin syndrome. Which treatment and when?]. Presse Med (2001) 0.90
The link between sunshine and phototoxicity of sparfloxacin. Br J Clin Pharmacol (2000) 0.89
A global role for zebrafish klf4 in embryonic erythropoiesis. Mech Dev (2007) 0.89
[Factorial structure of the Hamilton depression scale. I]. Ann Med Psychol (Paris) (1981) 0.88
The value of scintigraphic studies in the assessment of patients with acute or chronic gastrointestinal haemorrhage. Nucl Med Commun (1993) 0.88
Body water compartment measurements: a comparison of bioelectrical impedance analysis with tritium and sodium bromide dilution techniques. Clin Nutr (2001) 0.88
Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595. J Clin Oncol (2000) 0.87
Effect of bran, ispaghula, and inert plastic particles on gastric emptying and small bowel transit in humans: the role of physical factors. Gut (1997) 0.87
Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment Pharmacol Ther (2000) 0.87
Factorial structure of the 20-item Toronto Alexithymia Scale: confirmatory factorial analyses in nonclinical and clinical samples. J Psychosom Res (2001) 0.87
Euglycaemic hyperinsulinaemia does not affect gastric emptying in type I and type II diabetes mellitus. Diabetologia (1999) 0.87
Pharmacotherapy of depression and mixed states in bipolar disorder. J Affect Disord (2000) 0.87
Factorial structure of the 17-item Hamilton Depression Rating Scale. Acta Psychiatr Scand (1995) 0.87
A comparison of iodine and indium labelled anti CEA intact antibody, F(ab)2 and Fab fragments by imaging tumour xenografts. Eur J Nucl Med (1988) 0.86
Factors predictive of ten-year mortality in severe anorexia nervosa patients. Acta Psychiatr Scand (2010) 0.86
Comparative imaging and biodistribution studies with an anti-CEA monoclonal antibody and its F(ab)2 and Fab fragments in mice with colon carcinoma xenografts. Eur J Nucl Med (1986) 0.86
In vivo localization of anti-osteogenic sarcoma 791T monoclonal antibody in osteogenic sarcoma xenografts. Int J Cancer (1982) 0.86
More on fluoroquinolone antibiotics and tendon rupture. N Engl J Med (1995) 0.86
Biodistribution of a monoclonal antibody-methotrexate conjugate (791T/36-MTX) in patients with colorectal cancer. Int J Cancer Suppl (1988) 0.85
Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment and during alcohol abstinence. Neuropsychobiology (2004) 0.85
Anhedonia and blunted affect in major depressive disorder. Compr Psychiatry (1995) 0.85
Reproducibility of gastric emptying of a pancake and milkshake meal in normal subjects. Nucl Med Commun (1998) 0.85
The effect of food on the systemic availability of ketoprofen. Eur J Clin Pharmacol (1988) 0.85
An integrated methodology for data processing in dynamic force spectroscopy of ligand-receptor binding. Ultramicroscopy (2007) 0.84
Pharmacokinetics of salicylates in elderly. Gerontology (1979) 0.84
Effects of a 5-HT(3) antagonist, ondansetron, on fasting and postprandial small bowel water content assessed by magnetic resonance imaging. Aliment Pharmacol Ther (2010) 0.84
Photoinduced cyclic electron transfer in Rhodocyclus tenuis cells: participation of HiPIP or cyt c8 depending on the ambient redox potential. Biochemistry (1997) 0.84
Physical anhedonia in major depressive disorder. J Affect Disord (1992) 0.84
Differences in tumour and normal tissue concentrations of iodine- and indium-labelled monoclonal antibody. II. Biodistribution studies in mice with human tumour xenografts. Eur J Nucl Med (1985) 0.84
The duration of bleeding following varicose vein stripping. Clin Phys Physiol Meas (1983) 0.83
Searching-waiting strategy: a candidate for an evolutionary model of depression? Behav Neural Biol (1984) 0.83
Diffusion of intramuscular ketoprofen into the cerebrospinal fluid. Eur J Clin Pharmacol (1985) 0.83
Preclinical evaluation of copper-67 labelled anti-MUC1 mucin antibody C595 for therapeutic use in bladder cancer. Eur J Nucl Med (1997) 0.83
Targeting of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate to the hepatocyte galactose-receptor in mice: visualisation and quantification by gamma scintigraphy as a basis for clinical targeting studies. J Drug Target (1993) 0.83
Localization of an anti-CEA monoclonal antibody in colo-rectal carcinoma xenografts. Cancer Immunol Immunother (1985) 0.82
Changes in 86-rubidium uptake in erythrocytes of digoxin-treated patients, in heart failure with sinus rhythm. Relationship to clinical effects. Eur J Cardiol (1981) 0.82
Gamma scintigraphy of a 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma. J Drug Target (1996) 0.82
Switching to the bingeing/purging subtype of anorexia nervosa is frequently associated with suicidal attempts. Eur Psychiatry (2007) 0.82
Ocular contact time of a carbomer gel (GelTears) in humans. Br J Ophthalmol (1998) 0.82
Scintigraphic assessment of the intragastric distribution and gastric emptying of an encapsulated drug: the effect of feeding and of a proton pump inhibitor. Aliment Pharmacol Ther (1994) 0.82
The effects of amrinone on cardiac function, oxygen consumption and lactate production of an isolated, perfused, working guinea-pig heart. Arch Int Pharmacodyn Ther (1983) 0.81
Imaging for staging bladder cancer: a clinical study of intravenous 111indium-labelled anti-MUC1 mucin monoclonal antibody C595. BJU Int (2001) 0.81
Biodistribution of 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01. Cancer Immunol Immunother (1998) 0.81
Immunoscintigraphy of small-cell lung cancer: a study using technetium and indium labelled anti-carcinoembryonic antigen monoclonal antibody preparations. Br J Cancer (1993) 0.81
Gamma scintigraphy of the biodistribution of 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in mice with transplanted melanoma and mammary carcinoma. J Drug Target (1996) 0.81
Effect of euglycaemic hyperinsulinaemia on gastric emptying and gastrointestinal hormone responses in normal subjects. Diabetologia (1998) 0.81
Stool water content and colonic drug absorption: contrasting effects of lactulose and codeine. Pharm Res (1999) 0.81
Iodine-131 and indium-111 labelled avidin and streptavidin for pre-targetted immunoscintigraphy with biotinylated anti-tumour monoclonal antibody. Nucl Med Commun (1988) 0.80
Night-time quiescence and morning activation in the human colon: effect on transit of dispersed and large single unit formulations. Eur J Gastroenterol Hepatol (1999) 0.80
Quality of life in schizophrenics with and without the deficit syndrome. Eur Psychiatry (2004) 0.80